This is a Phase 1, randomized, double-blind, placebo-controlled, single dose-escalation
first-in human study to evaluate the safety, tolerability, PK, PD and immunogenicity of AK111
in healthy subjects following SC administration. The study will consist of cohorts of healthy
subjects. Cohort 1, four unique subjects will be randomized to receive either active AK111
(N=3) or matching placebo (N=1). Cohorts 2, 3, 4 and 5, eight unique subjects will be
randomized to receive either active AK111 (N=6) or matching placebo (N=2). Approximately 36
subjects will be treated in this study.